Medication · Also: Ozempic, Wegovy, Rybelsus

Semaglutide

A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.

A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.

Also known as: Ozempic, Wegovy, Rybelsus

Semaglutide is a GLP-1 receptor agonist. The FDA has approved branded semaglutide products for type 2 diabetes (Ozempic, Rybelsus) and for chronic weight management (Wegovy).

It is given as a once-weekly injection or, in one form, a daily tablet. Use, dosing, and monitoring are directed by a prescriber.

Related terms

GLP-1

A class of medicines that mimic the gut hormone GLP-1 to lower blood sugar and reduce appetite.

Tirzepatide

A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management.

Ozempic

A brand of injectable semaglutide FDA-approved to treat type 2 diabetes.

Wegovy

A brand of injectable semaglutide FDA-approved for chronic weight management.

Source

DailyMed: Semaglutide

← Back to full glossary